British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the ...

FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the ...

London: GSK plc has announced that the US Food and Drug Administration (FDA) has accepted for review an application to extend ...

New: The FDA has expanded the approval for GSK’s vaccine to protect against respiratory syncytial virus, or RSV, authorizing its use for at-risk adults as young as 50.

Phase 3 clinical trial data showed the GSK vaccine had an efficacy of 82.6% in preventing confirmed lower respiratory tract disease caused by RSV. The vaccine includes an adjuvant, a compound that ...

GSK plc (GSK) said on Monday that its application for extending the use of its respiratory syncytial virus (RSV) vaccine Arexvy to adults aged 18-49 who are at increased risk of contracting the ...

Preliminary data from GSK shows its RSV vaccine, Arexvy, could help protect people ages 50 to 59 against the virus. Leon Neal/Getty Images/FILE. CNN — ...

The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and Pfizer's PFE.N Abrysvo.

GSK’s vaccines rouse the body’s immunity with an RSV surface protein called the F glycoprotein. Before the virus breaks in and enters the host cell, it exists in a lollipop-shaped prefusion form .

A single dose of the shot was 67.2% effective in preventing lower respiratory tract illness over two RSV seasons, according to new results from a phase three clinical trial. That's compared with ...